Charity Tarn, investor with Arboretum Ventures and one of the judges at the MedCity News INVEST 2025 event, says that although the investment landscape for startups has been tough, raising capital through efficient and defined methods favourable to future financing needs is becoming more prevalent. Tarn also sees a switch in investor priorities to more low-risk investments with predictable business models.
Startup OMass Secures $310M to Advance Drug for Rare Endocrine Disorder
OMass’s molecule is vying to become an alternative to a Neurocrine Biosciences drug that is currently the only FDA-approved therapy for congenital adrenal hyperplasia. But
